Proteasome Inhibition Induces Both Antioxidant and Hb F Responses in Sickle Cell Disease Via the Nrf2 Pathway

被引:17
作者
Pullarkat, Vinod [1 ]
Meng, Zhuo [1 ]
Tahara, Stanley M. [2 ]
Johnson, Cage S. [1 ]
Kalra, Vijay K. [3 ]
机构
[1] Univ So Calif, Keck Sch Med, Jane Ann Nohl Div Hematol, Los Angeles, CA 90033 USA
[2] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA
[3] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA
关键词
Antioxidant response; Hb F; nuclear factor (erythroid-derived 2)-like 2 (NFE2L2 of Nrf2); proteasome inhibitors; reactive oxygen species (ROS); sickle cell disease; HUMAN ENDOTHELIAL-CELLS; FETAL-HEMOGLOBIN; MULTIPLE-MYELOMA; IN-VITRO; RISK-FACTORS; HYDROXYUREA; INDUCTION; EXPRESSION; THERAPY; ANEMIA;
D O I
10.3109/03630269.2014.898651
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oxidant stress is implicated in the manifestations of sickle cell disease including hemolysis and vascular occlusion. Strategies to induce antioxidant response as well as Hb F (alpha 2 gamma 2) have the potential to ameliorate the severity of sickle cell disease. Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2 or Nrf2) is a transcription factor that regulates antioxidant enzymes as well as gamma-globin transcription. The Nrf2 in the cytoplasm is bound to its adapter protein Keap-1 that targets Nrf2 for proteasomal degradation, thereby preventing its nuclear translocation. We examined whether inhibiting the 26S proteasome using the clinically applicable proteasome inhibitors bortezomib and MLN 9708 would promote nuclear translocation of Nrf2, and thereby induce an antioxidant response and as well as Hb F in sickle cell disease. Proteasome inhibitors induced reactive oxygen species (ROS) and thereby increased Nrf2-dependent antioxidant enzyme transcripts, elevated cellular glutathione (GSH) levels and gamma-globin transcripts as well as Hb F levels in the K562 cell line and also in erythroid burst forming units (BFU-E) generated from peripheral blood mononuclear cells of sickle cell disease patients. These responses were abolished by siRNA-mediated knockdown of Nrf2. Proteasome inhibitors, especially newer oral agents such as MLN9708 have the potential to be readily translated to clinical trials in sickle cell disease with the dual end points of antioxidant response and Hb F induction.
引用
收藏
页码:188 / 195
页数:8
相关论文
共 33 条
[1]   Fetal hemoglobin in sickle cell anemia [J].
Akinsheye, Idowu ;
Alsultan, Abdulrahman ;
Solovieff, Nadia ;
Duyen Ngo ;
Baldwin, Clinton T. ;
Sebastiani, Paola ;
Chui, David H. K. ;
Steinberg, Martin H. .
BLOOD, 2011, 118 (01) :19-27
[2]   The cytoprotective role of the Keap1-Nrf2 pathway [J].
Baird, Liam ;
Dinkova-Kostova, Albena T. .
ARCHIVES OF TOXICOLOGY, 2011, 85 (04) :241-272
[3]   Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders [J].
Bauer, Daniel E. ;
Kamran, Sophia C. ;
Orkin, Stuart H. .
BLOOD, 2012, 120 (15) :2945-2953
[4]  
Chandra J, 2009, ANTIOXID REDOX SIGN, V11, P1123, DOI [10.1089/ars.2008.2302, 10.1089/ARS.2008.2302]
[5]   In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells [J].
Chauhan, Dharminder ;
Tian, Ze ;
Zhou, Bin ;
Kuhn, Deborah ;
Orlowski, Robert ;
Raje, Noopur ;
Richardson, Paul ;
Anderson, Kenneth C. .
CLINICAL CANCER RESEARCH, 2011, 17 (16) :5311-5321
[6]   Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy [J].
Dick, Lawrence R. ;
Fleming, Paul E. .
DRUG DISCOVERY TODAY, 2010, 15 (5-6) :243-249
[7]   Progress in Understanding the Hemoglobin Switch [J].
Forget, Bernard G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (09) :852-854
[8]   In vitro induction of fetal hemoglobin in human erythroid progenitor cells [J].
Ho, JA ;
Pickens, CV ;
Gamscik, MP ;
Colvin, OM ;
Ware, RE .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (07) :586-591
[9]   Small molecule modulators of antioxidant response pathway [J].
Hur, Wooyoung ;
Gray, Nathanael S. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2011, 15 (01) :162-173
[10]  
Kato Gregory J, 2009, Am J Hematol, V84, P618, DOI 10.1002/ajh.21475